Alto Neuroscience, Inc. (ANRO) Stock

NYSE: ANROCombines neuroscience and artificial intelligence to develop precision therapies for mental health conditions.

Alto Neuroscience stock price chart

ANRO interactive chart →

ANRO stock quote & key statistics

Alto Neuroscience earnings per share

Income →
Earnings per share

Alto Neuroscience revenue & net income

Income →
RevenueNet income

Alto Neuroscience annual financials

Income statement →
Fiscal yearRevenueNet incomeEPS
FY2025$0-$63.2M-$2.25
FY2024$0-$61.4M-$9.75
FY2023$0-$36.3M—
FY2022$0-$27.7M—
FY2021$210,000-$9.2M—

Fiscal year ending September 30. Source: company filings via EODHD.

About Alto Neuroscience, Inc.

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprises ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.

The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD.

In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient.

The company was incorporated in 2019 and is headquartered in Los Altos, California.

Alto Neuroscience stock FAQ

What is the Alto Neuroscience stock ticker symbol?

Alto Neuroscience, Inc. trades on the NYSE under the ticker symbol ANRO.

What sector and industry is Alto Neuroscience in?

Alto Neuroscience, Inc. is classified in the Healthcare sector, Biotechnology industry.

How many employees does Alto Neuroscience have?

Alto Neuroscience, Inc. has about 68 full-time employees.

What were Alto Neuroscience's revenue and earnings last fiscal year?

Alto Neuroscience reported revenue of $0 and net income of -$63.2M in fiscal 2025, with earnings per share of -$2.25.

Is Alto Neuroscience in the Russell 2000?

Yes. Alto Neuroscience, Inc. (ANRO) is a component of the Russell 2000, the benchmark index of U.S. small-cap stocks.

When did Alto Neuroscience go public?

Alto Neuroscience stock began trading on February 2, 2024.

Russell 2000 Biotechnology stocks

All Russell 2000 →